Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer

NDAQ:APHA - Post by User

Aphria Inc.

Bullboard Posts

Comment by jayjay2020on Aug 01, 2019 5:32pm

121 Views

Post# 29986386

RE:RE:RE:We made a profit !!!!

WebSwinger wrote: Im thinking that the 50 million may have added 50 million to revenue. So without the 50 million then they would have got 78 million revenue. So why did they get 59 million from a green growth thing.

WebSwinger wrote: I dont understand this point.

Settlement of Green Growth Brands takeover bid resulting in $50 million cash received and an additional $39 million to be received in November.

Why would Aphria get 50 million. I hope this isn’t the only reason they did so well. Does this mean with out the 50 million they would have had 50 million less in revenue. I must be not understanding the quote.

jayjay2020 wrote:

Net revenue of $128.6 million in the fourth quarter, an increase of 75% from prior quarter and 969% from prior year.

Revenue for adult-use cannabis of $18.5 million in the fourth quarter, up 158% from prior quarter.

Net income of $15.8 million and adjusted EBITDA of $0.2 million in the fourth quarter.

Adjusted EBITDA from cannabis operations of $1.9 million in the fourth quarter.

Closed a 5.25% convertible senior notes offering for net proceeds of over US $335 million .

Ended quarter with a strong balance sheet and liquidity, including $571 million of cash, cash equivalents and liquid marketable securities, to fund planned Canadian and International growth.

Settlement of Green Growth Brands takeover bid resulting in $50 million cash received and an additional $39 million to be received in November.

Planted more than 200,000 plants in the new expanded area of Aphria One cultivation.

On-track for annual production capacity of 255,000 kilograms when all facilities are fully licensed.

Granted the maximum amount of lots within the German tender process, a total of five, and is the only licensed producer in Germany with the permission to grow all three strains of medical cannabis approved by the German Federal Institute for Drugs and Medical Devices.

Introduced a CBD-based nutraceutical product line for the German market.

Enhanced the executive team with appointment of several key positions.